Docetaxel

Docetaxel, a semisynthetic analog of paclitaxel, shares the latter's mechanism of action: the promotion of microtubule assembly and inhibition of microtubule disassembly. This anti-mitotic behavior results in apoptosis of human leukemia HL-60 cells arrested at the M phase in the cell cycle. Docetaxel has exhibited significant antitumor activity against prostate cancer, metastatic breast cancer, gastric cancer, and others. Docetaxel is the active ingredient in the drug product sold under the trade name Taxotere®. This drug is currently approved in at least one country for use in patients with Breast Cancer, Non Small Cell Lung Cancer, Hormone Refractory Prostrate Cancer, and many other conditions NOTE: The Docetaxel sold by Cfm Oskar Tropitzsch GmbH for R&D is not TAXOTERE®, and is nor for human use. Potential mode of action/Key words: Targeting Tubulin, Inhibition of microtubule assembly, Induces Apoptosis